Question 1

What do medical sources say about Promethazine (Phenergan, Promethegan, Phenadoz) during pregnancy?

Accepted Answer

1st Trimester: MotherToBaby says promethazine use in pregnancy is not expected to raise the chance of birth defects. In a Hungarian case-control study of 22,843 birth-defect cases and 38,151 controls, early findings involving cleft lip or palate and extra or joined fingers or toes were not confirmed when analysis was limited to medically recorded use; the overall results did not suggest more abnormalities at clinical doses. MotherToBaby reports one small study did not find more miscarriages, while a 1976 study of 6,376 pregnancies evaluated antiemetics as a group rather than promethazine alone. The NHS says promethazine can be taken in pregnancy, while PHENERGAN tablet labeling says use only when potential benefit justifies fetal risk because adequate, controlled human studies are lacking. The tablet boxed warning prohibits direct use in children under 2 because of potentially fatal respiratory depression; a separate injection boxed warning describes severe tissue injury, including gangrene, with parenteral use, not tablets. Ask your provider about your situation. 2nd Trimester: MotherToBaby says promethazine is not expected to raise the chance of birth defects, but it does not know whether use changes the chance of preterm delivery or low birth weight. The pregnancy studies reviewed do not give a separate second-trimester risk estimate. The NHS says promethazine can be taken in pregnancy, while PHENERGAN tablet labeling says use only when potential benefit justifies fetal risk because adequate, controlled human studies are lacking. MotherToBaby reports one small study did not find more miscarriages, but the available 1976 study assessed antiemetics as a group and did not isolate promethazine. The tablet boxed warning prohibits direct use in children under 2 because of potentially fatal respiratory depression; a separate injection boxed warning describes severe tissue injury, including gangrene, with parenteral use, not tablets. Ask your provider about your situation. 3rd Trimester: MotherToBaby says reports suggest that late-pregnancy promethazine might slow a newborn's breathing and that the care team should know about its use. PHENERGAN tablet labeling says use within two weeks of delivery may affect how newborn platelets clump. The tablet label also says adequate, controlled human pregnancy studies are lacking and use depends on whether potential benefit justifies fetal risk. MotherToBaby does not know whether promethazine affects preterm delivery or low birth weight, and the studies reviewed do not provide a separate third-trimester estimate. The tablet boxed warning prohibits direct use in children under 2 because of potentially fatal respiratory depression; a separate injection boxed warning describes severe tissue injury, including gangrene, with parenteral use, not tablets. Ask your provider about your situation.

Question 2

What do medical sources say about Promethazine (Phenergan, Promethegan, Phenadoz) while breastfeeding?

Accepted Answer

LactMed and MotherToBaby report that published studies have not measured promethazine in human milk or infant blood and have not reported direct effects in breastfed babies. The NHS says milk levels are likely to be low and recommends using promethazine only occasionally or briefly; NHS SPS advises occasional, short-term use with infant monitoring. LactMed advises watching for excess sleepiness with repeated doses, and MotherToBaby says sleepiness and reduced milk supply are possible, especially early in breastfeeding. The PHENERGAN tablet label says it is not known whether the drug enters human milk and describes weighing treatment against nursing; the under-two boxed warning concerns direct dosing, not exposure through milk. The separate injection boxed warning describes severe tissue injury, including gangrene, with parenteral use, not tablets. Ask your provider about your situation.

Question 3

Where do sources disagree on Promethazine (Phenergan, Promethegan, Phenadoz) in pregnancy or breastfeeding?

Accepted Answer

How to describe promethazine use in early and mid pregnancy when controlled studies are absent The PHENERGAN tablet label says adequate, well-controlled studies in pregnant women are lacking and that use should occur only when potential benefit justifies potential fetal risk. MotherToBaby says promethazine is not expected to increase birth-defect chance, and the NHS says it can be taken in pregnancy. The label states that adequate controlled human pregnancy studies are lacking and gives a product benefit-risk precaution. MotherToBaby and the NHS summarize observational information and clinical experience. The label wording does not establish that human fetal harm was found. The available observational evidence does not show an overall increase in congenital abnormalities at clinical doses, while the product label's data-limited precaution remains important. The sources' different emphasis is shown here rather than treated as proof of a harm signal.

Promethazine

Promethazine — Breastfeeding

What the research shows

What's in it / what was tested

Sources disagree

Options sources describe

Beyond pregnancy

All sources

Similar medications